Armata's Q2 Loss Widens Amidst R&D Spend, Secures New Loan

TL;DR

**Armata's widening losses and reliance on debt signal a tough road ahead, making it a speculative bet on future drug success.**

AI Summary

Armata Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a clinical-stage biotechnology company. The company incurred a net loss of $10.5 million for the three months ended June 30, 2025, an increase from a net loss of $9.8 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $20.8 million, up from $19.5 million in the first half of 2024. Research and development expenses were $7.5 million for the three months ended June 30, 2025, compared to $7.0 million in the prior year, reflecting ongoing clinical trial activities. General and administrative expenses increased to $3.0 million from $2.8 million year-over-year for the quarter. A significant strategic change was the entry into a new Credit Agreement with Innoviva Strategic Opportunities LLC on March 12, 2025, providing a secured term loan facility. The company's primary risk remains its dependence on successful clinical development and regulatory approval of its product candidates, as well as its ability to secure additional funding to support operations, given its accumulated deficit of $400.0 million as of June 30, 2025.

Why It Matters

Armata's continued net losses and lack of revenue underscore the high-risk, high-reward nature of clinical-stage biotech investing. The new secured term loan from Innoviva Strategic Opportunities LLC provides a critical, albeit temporary, lifeline, indicating ongoing investor confidence in their phage therapy pipeline, but also highlights the company's persistent need for capital. For investors, this means continued dilution risk or further debt financing will be necessary to fund operations beyond the near term. Employees and customers are directly impacted by the company's ability to advance its drug candidates, particularly in the competitive antimicrobial resistance space, where successful development could offer significant medical breakthroughs.

Risk Assessment

Risk Level: high — Armata Pharmaceuticals faces a high risk level due to its consistent lack of revenue and increasing net losses, reporting a net loss of $10.5 million for Q2 2025 and an accumulated deficit of $400.0 million as of June 30, 2025. The company's dependence on external financing, evidenced by the new secured term loan from Innoviva Strategic Opportunities LLC, indicates significant going concern risks without successful clinical development and commercialization.

Analyst Insight

Investors should approach ARMP with extreme caution, recognizing it as a highly speculative investment. Monitor progress on clinical trials and future financing rounds closely, as the company's viability hinges on successful drug development and securing substantial additional capital.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue for Q2 2025 and YTD 2025, consistent with prior periods.)
• -$10.5M — Net Loss (Q2 2025) (Increased from -$9.8M in Q2 2024, indicating widening losses.)
• -$20.8M — Net Loss (YTD 2025) (Increased from -$19.5M in YTD 2024, showing higher burn rate.)
• $7.5M — R&D Expenses (Q2 2025) (Increased from $7.0M in Q2 2024, reflecting ongoing clinical activities.)
• $400.0M — Accumulated Deficit (As of June 30, 2025, highlighting significant historical losses.)
• March 12, 2025 — Credit Agreement Date (Date of new secured term loan facility with Innoviva Strategic Opportunities LLC.)

Key Players & Entities

• Armata Pharmaceuticals, Inc. (company) — filer of the 10-Q
• Innoviva Strategic Opportunities LLC (company) — lender in the new Credit Agreement
• $10.5 million (dollar_amount) — net loss for Q2 2025
• $9.8 million (dollar_amount) — net loss for Q2 2024
• $20.8 million (dollar_amount) — net loss for six months ended June 30, 2025
• $19.5 million (dollar_amount) — net loss for six months ended June 30, 2024
• $7.5 million (dollar_amount) — research and development expenses for Q2 2025
• $7.0 million (dollar_amount) — research and development expenses for Q2 2024
• $3.0 million (dollar_amount) — general and administrative expenses for Q2 2025
• $400.0 million (dollar_amount) — accumulated deficit as of June 30, 2025

FAQ

Risk Factors

• Dependence on Future Funding [high — financial]: Armata Pharmaceuticals has an accumulated deficit of $400.0 million as of June 30, 2025. The company's ability to continue as a going concern is highly dependent on its ability to secure additional funding to support its ongoing operations and clinical development programs.
• Clinical Development and Regulatory Approval Risk [high — regulatory]: The company's primary risk is the successful clinical development and subsequent regulatory approval of its product candidates. Failure to achieve these milestones would significantly impact the company's future prospects and ability to generate revenue.
• Increasing Net Losses [medium — financial]: For the three months ended June 30, 2025, Armata reported a net loss of $10.5 million, an increase from $9.8 million in the prior year. The year-to-date net loss also widened to $20.8 million from $19.5 million, indicating a higher burn rate.
• Rising R&D and G&A Expenses [medium — operational]: Research and development expenses increased to $7.5 million for Q2 2025 from $7.0 million in Q2 2024, reflecting ongoing clinical trial activities. General and administrative expenses also rose to $3.0 million from $2.8 million year-over-year for the quarter.
• Debt Financing Reliance [medium — financial]: The company entered into a new Credit Agreement with Innoviva Strategic Opportunities LLC on March 12, 2025, for a secured term loan facility. While this provides capital, it increases the company's debt obligations and reliance on lenders.

Industry Context

Armata Pharmaceuticals operates in the highly competitive biotechnology sector, characterized by long development cycles, significant R&D investment, and high failure rates. Companies in this space are heavily reliant on scientific innovation, clinical trial success, and regulatory approvals to bring products to market. The industry is driven by advancements in science and technology, with a constant need for capital to fund research and development.

Regulatory Implications

As a clinical-stage company, Armata faces significant regulatory hurdles. The success of its product candidates hinges on rigorous clinical trials and obtaining approval from regulatory bodies like the FDA. Any delays or failures in the regulatory process pose a substantial risk to the company's future viability.

What Investors Should Do

1. Monitor cash burn and future funding rounds.
2. Evaluate progress in clinical trials.
3. Assess the impact of the new credit facility.

Key Dates

• 2025-03-12: Entered into Credit Agreement with Innoviva Strategic Opportunities LLC — Secured a new term loan facility, providing potential capital but also increasing debt obligations.
• 2025-06-30: Quarter and Six-Month Period End — Reporting period for the 10-Q, showing increased net losses and R&D expenses.

Glossary

Clinical-stage biotechnology company

A company focused on developing new drugs or therapies that are currently undergoing testing in human subjects (clinical trials) to assess their safety and efficacy. (Explains why Armata Pharmaceuticals has no revenue and incurs significant R&D expenses.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, representing the excess of expenses over revenues over time. (Highlights Armata's significant historical unprofitability, standing at $400.0 million as of June 30, 2025.)

Secured Term Loan Facility

A type of loan that is backed by specific collateral, providing the lender with a claim on certain assets if the borrower defaults. A term loan has a specified repayment schedule. (Refers to the new financing obtained from Innoviva Strategic Opportunities LLC, which is secured by company assets.)

Year-Over-Year Comparison

Compared to the prior year periods, Armata Pharmaceuticals reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. However, net losses have widened, with Q2 2025 losses increasing to $10.5 million from $9.8 million and year-to-date losses rising to $20.8 million from $19.5 million. Research and development expenses also saw a modest increase, reflecting continued investment in its pipeline. A significant development is the new credit agreement entered into in March 2025, indicating a reliance on debt financing.

Key Financial Figures

• $0.01 — ge on which registered Common Stock , $0.01 par value per share ARMP NYSE Ameri
• $26.2 million — the expected use of proceeds from the $26.2 million DoD award; the effects of government r

Filing Documents

• armp-20250630x10q.htm (10-Q) — 1542KB
• armp-20250630xex31d1.htm (EX-31.1) — 15KB
• armp-20250630xex31d2.htm (EX-31.2) — 15KB
• armp-20250630xex32d1.htm (EX-32.1) — 8KB
• armp-20250630xex32d2.htm (EX-32.2) — 8KB
• armp-20250630x10q001.jpg (GRAPHIC) — 53KB
• 0001558370-25-011235.txt ( ) — 6900KB
• armp-20250630.xsd (EX-101.SCH) — 46KB
• armp-20250630_cal.xml (EX-101.CAL) — 50KB
• armp-20250630_def.xml (EX-101.DEF) — 178KB
• armp-20250630_lab.xml (EX-101.LAB) — 398KB
• armp-20250630_pre.xml (EX-101.PRE) — 319KB
• armp-20250630x10q_htm.xml (XML) — 1174KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations 7 Condensed Consolidated Statements of Stockholders' Deficit 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37

OTHER INFORMATION

PART II. OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 38

SIGNATURES

SIGNATURES 41 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") and certain information incorporated herein by reference contain forward-looking statements, which are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to our future financial performance and involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or events to be materially different from any future results, performance, or events expressed or implied by the forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding: our estimates regarding anticipated operating losses, capital requirements and needs for additional funds; our ability to raise additional capital when needed and to continue as a going concern; our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials; our clinical development plans, including planned clinical trials; our research and development plans; our ability to select combinations of phages to formulate our product candidates; our development of bacteriophage-based therapies; the potential use of bacteriophages to treat bacterial infections; the potential future of antibiotic resistance; the ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivity to antibiotics; the potential for bacteriophage technology being uniquely positioned to address the global threat of antibiotic resistance; our planned development strategy, presenting data to regulatory agencies and defining planned clinical studies; the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials; our ab

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS Armata Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 4,328 $ 9,291 Prepaid expenses and other current assets 1,024 1,273 Other receivables 2,168 744 Total current assets 7,520 11,308 Restricted cash 5,390 5,480 Property and equipment, net 12,657 13,241 Operating lease right-of-use asset 40,504 41,687 In-process research and development 10,256 10,256 Goodwill 3,490 3,490 Other assets 973 975 Total assets $ 80,790 $ 86,437 Liabilities and stockholders' deficit Current liabilities Accounts payable and accrued liabilities $ 1,540 $ 2,055 Accrued compensation 1,584 2,280 Convertible Loan, current 33,445 — Term debt, current 78,891 38,954 Current portion of operating lease liabilities 4,488 4,431 Other current liabilities 137 529 Total current liabilities 120,085 48,249 Convertible Loan, non-current — 32,897 Term debt, non-current — 22,539 Operating lease liabilities, net of current portion 27,131 27,694 Deferred tax liability 3,077 3,077 Total liabilities 150,293 134,456 Commitments and contingencies (Note 12) Stockholders' deficit Common Stock, $ 0.01 par value; 217,000,000 shares authorized; 36,193,479 and 36,183,067 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 362 362 Additional paid-in capital 280,696 279,354 Accumulated deficit ( 350,561 ) ( 327,735 ) Total stockholders' deficit ( 69,503 ) ( 48,019 ) Total liabilities and stockholders' deficit $ 80,790 $ 86,437 See accompanying notes to condensed consolidated financial statements. 6 Table of Contents Armata Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and pe

View Full Filing

View this 10-Q filing on SEC EDGAR